Mitsubishi Tanabe Takes Back Kremezin Marketing Rights From Daiichi Sankyo
This article was originally published in PharmAsia News
Executive Summary
In April, Mitsubishi Tanabe Pharma will regain the rights to market chronic kidney failure drug Kremezin (AST-120) in Japan from Daiichi Sankyo